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ABSTRACT
Objectives The Global Kidney Health Atlas (GKHA) is 
a multinational, cross- sectional survey designed to 
assess the current capacity for kidney care across all 
world regions. The 2017 GKHA involved 125 countries 
and identified significant gaps in oversight, funding and 
infrastructure to support care for patients with kidney 
disease, especially in lower- middle- income countries. 
Here, we report results from the survey for the second 
iteration of the GKHA conducted in 2018, which included 
specific questions about health financing and oversight of 
end- stage kidney disease (ESKD) care worldwide.
Setting A cross- sectional global survey.
Participants Key stakeholders from 182 countries were 
invited to participate. Of those, stakeholders from 160 
countries participated and were included.
Primary outcomes Primary outcomes included cost of 
kidney replacement therapy (KRT), funding for dialysis 
and transplantation, funding for conservative kidney 
management, extent of universal health coverage, out- 
of- pocket costs for KRT, within- country variability in 
ESKD care delivery and oversight systems for ESKD care. 
Outcomes were determined from a combination of desk 
research and input from key stakeholders in participating 
countries.
Results 160 countries (covering 98% of the world’s 
population) responded to the survey. Economic factors 
were identified as the top barrier to optimal ESKD care in 
99 countries (64%). Full public funding for KRT was more 
common than for conservative kidney management (43% 
vs 28%). Among countries that provided at least some 
public coverage for KRT, 75% covered all citizens. Within- 
country variation in ESKD care delivery was reported in 
40% of countries. Oversight of ESKD care was present in 
all high- income countries but was absent in 13% of low- 
income, 3% of lower- middle- income, and 10% of upper- 
middle- income countries.
Conclusion Significant gaps and variability exist in 
the public funding and oversight of ESKD care in many 
countries, particularly for those in low- income and lower- 
middle- income countries.
INTRODUCTION
The prevalence of kidney disease is increasing 
rapidly, accounting for 1.2 million deaths 
in 2015—an increase of 32% since 2005.1 2 
Strengths and limitations of this study
 ► The study included 160 countries (covering 98% of 
the world’s population), which provided a compre-
hensive overview of the state of kidney care around 
the world.
 ► The study combined findings from desk research as 
well as survey responses from on- the- ground stake-
holders to provide a holistic perspective of kidney 
care in participating countries.
 ► The 2019 report was the second iteration of the 
Global Kidney Health Atlas and allowed for monitor-
ing of progress made since the previous report and 
identification of new and ongoing gaps.
 ► Data available from low- income countries were lim-
ited compared to middle- income and high- income 
countries, which led to challenges in identifying spe-
cific gaps in care provision in nations where this was 
greatly needed.
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Kidney disease is roughly twice as prevalent as diabetes 
and 20 times more prevalent than cancer or HIV/AIDS.3 
In 2013, chronic kidney disease (CKD) was one of the top 
10 causes of years of life lost and/or disability adjusted life 
years in 51 countries.4 Of the estimated 4.9–9.7 million 
people in need of kidney replacement therapy (KRT) for 
end- stage kidney disease (ESKD) in 2010, only 2.6 million 
had access.5 The number of people requiring KRT is 
projected to increase to 14.5 million by 2030, with only 
5.4 million people likely to have access if current trends 
continue. Only 4% of people in low- income and middle- 
income countries who require KRT have access, compared 
with 60% of people in high- income countries.5
The global burden of kidney disease can be reduced 
by access to universal health coverage (UHC), which is 
the cornerstone of health equity. All 192 WHO member 
states committed to implementing UHC in 2005 and 
recently recommitted to achieving this goal by 2030 at the 
UN General Assembly High- Level Meeting on Universal 
Health Coverage.6 Successful delivery of UHC requires 
adequate health financing and effective leadership and 
governance,7 which have been identified by the WHO as 
two of the six building blocks necessary for a functioning 
health system.8 Poor governance practices, such as inad-
equate resource allocation and unstructured care provi-
sion, are closely correlated with increased prevalence of 
ESKD.9 Within individual countries, those who are most 
vulnerable or disadvantaged are at higher risk of incident 
CKD and rapid disease progression.1
The Global Kidney Health Atlas (GKHA) is a multina-
tional, cross- sectional survey designed to assess the current 
capacity for kidney care across all world regions. The 2017 
GKHA involved 125 countries and identified significant 
gaps in oversight, funding and infrastructure to support 
care for patients with kidney disease, especially in lower- 
middle- income countries.2 The report found that roughly 
half of countries worldwide provided public funding for 
acute kidney injury (AKI) treatment (56%), non- dialysis 
CKD treatment (40%), dialysis (63%) and transplantation 
(57%).2 Funding was less common in lower- income coun-
tries, with countries in Africa and Southeast Asia being 
more likely to rely on private funding and out- of- pocket 
expenditure.2 Some countries in Africa and the Middle 
East reported no organised healthcare system.2 Perceived 
quality of healthcare infrastructure for AKI and CKD care 
was poor in 40% of low- income countries, particularly in 
Africa.2 Here, we report results from the survey for the 
second iteration of the GKHA conducted in 2018, which 
included specific questions about health financing and 
oversight of ESKD care worldwide. Oversight has been 
defined as the body responsible for ensuring effective 
delivery of kidney care.
METHODS
Two data collection methods were used for the second 
iteration of the GKHA: desk research (review of available 
literature) and an online survey of key stakeholders from 
each country. Details about the design, validation and 
distribution of the online survey, data analysis techniques 
and original questionnaire have been reported else-
where.10 11 The project was funded by the International 
Society of Nephrology (ISN), and all survey participants 
provided informed consent.
Desk research
Data sources included literature reviews, databases, the 
WHO Global Health Observatory, surveys, interviews 
and the WHO Non- Communicable Disease Strategy. A 
scoping review of published articles and grey literature 
was also performed to extract estimates of the annual 
costs of maintenance haemodialysis (HD), maintenance 
peritoneal dialysis (PD) and kidney transplantation in the 
first year and subsequent years and of the cost ratio of 
maintenance HD to PD. Since included studies were from 
different years and from countries with different curren-
cies, reported costs were converted to international 
dollars (2016 US$) using standard techniques (online 
supplemental figure 1).
Country survey
A project leader from each of the 10 ISN regions identi-
fied three key stakeholders (a nephrology society leader, 
a leader of a consumer representative organisation and a 
policymaker) for each country in his or her region (182 
countries total). The stakeholders were subsequently 
invited by email to participate in the survey (available in 
English, French and Spanish) via an online portal ( www. 
redcapcloud. com) between July and September 2018. 
The survey data were used to provide information on 
funding for KRT and conservative kidney management, 
UHC, out- of- pocket costs for KRT, within- country varia-
tions in ESKD care delivery and oversight of ESKD care.
Analysis
Analysis was performed using a statistical analysis frame-
work (Assessing National Capacity for the Prevention and 
Control of Non- Communicable Diseases) developed by 
the WHO. World Bank income categories based on gross 
national income per capita in 2018 were used to classify 
countries as low- income, lower- middle- income, upper- 
middle- income and high- income countries.12 13 Results 
were analysed using a descriptive statistical approach 
and stratified by World Bank income group and ISN 
region. An emphasis was placed on identifying key gaps 
and challenges across domains based on a pre- existing 
protocol.11 14 Reporting followed the Guidelines for 
Accurate and Transparent Health Estimates Reporting 
statement12 and the Checklist for Reporting Results of 
Internet E- Surveys.13 The analyses were performed using 
Stata V.15 software (Stata Corporation, 2017).
RESULTS
Among the 182 countries surveyed, 160 responded, 
accounting for over 98% of the world’s population. 
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Economic factors were identified as the top barrier to 
optimal ESKD care (64%), followed by patient knowl-
edge and attitude (63%); nephrologist availability (60%); 
physician availability, access, knowledge and/or attitude 
(58%); capability of the healthcare system (55%); and 
distance from care or prolonged travel time (55%).
Cost of KRT
The annual cost of KRT (measured as 2016 US$) was 
highest in high- income countries and decreased as World 
Bank income group decreased (figure 1 and online 
supplemental table 1). In high- income countries, HD 
incurred higher costs per year than PD. Kidney transplan-
tation (first year) was costlier than either dialysis modality, 
but cost savings were significant in each subsequent year 
of post- transplant care. This trend continued in upper- 
middle- income countries, with the notable exception 
that kidney transplantation (first year) was less costly than 
dialysis. In lower- middle- income countries, the costs of 
HD and PD were comparable, with kidney transplanta-
tion (first year) being less costly than dialysis. Cost esti-
mates were only available for HD in low- income countries 
(figure 1 and online supplemental table 1).
Comparing costs of HD to PD, HD was more costly than 
PD in the majority of high- income and upper- middle- 
income countries, whereas PD was more costly than HD 
in the majority of lower- middle- income countries. Unfor-
tunately, insufficient data were available from low- income 
countries to compare costs (figure 2).
Funding for dialysis and transplantation
The average number of people receiving treatment for 
ESKD was 759 per million population (pmp) worldwide, 
with higher rates of treatment in high- income countries 
(969 pmp) compared with upper- middle- income (550.2 
pmp), lower- middle- income (321 pmp) and low- income 
countries (4.4 pmp), despite similar rates of ESKD inci-
dence in high- income (149 pmp), upper- middle- income 
(126 pmp) and lower- middle- income countries (129.9 
pmp).
Globally, public funding for KRT with no fees at 
point of delivery was available in 43% of countries, with 
an additional 21% offering public funding with some 
fees at the point of delivery (figure 3). Public funding 
for KRT was more prevalent in high- income countries 
(78%), with the highest rates of private and out- of- 
pocket funding in low- income countries (17%). Coun-
tries in the Middle East had the highest availability of full 
or partial public funding for KRT (100%), followed by 
Western Europe (91%), the Newly Independent States 
(NIS) and Russia (89%), North and East Asia (85%) 
and Eastern and Central Europe (84%) (figure 3). 
Medications for KRT patients were free at the point 
of delivery in 62% of countries overall, with an addi-
tional 21% offering public funding with some fees at 
the point of delivery. Medications were most likely to 
be fully covered in Eastern and Central Europe (95%), 
the Middle East (73%) and Western Europe (45%), 
with the lowest rates of coverage in North America 
and the Caribbean (11%), Africa (23%) and Latin 
America (28%). The proportion of countries providing 
full coverage for medications was much lower for low- 
income (19%) and lower- middle- income (23%) coun-
tries, compared with upper- middle- income (54%) and 
high- income (50%) countries (online supplemental 
table 2).
Medications for patients on KRT were covered in the 
minority (41%) of countries (online supplemental table 
2). The majority of countries (58%) provided some or 
Figure 1 Annual cost of kidney replacement therapy (KRT) modalities by World Bank income group.
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full public funding for the creation of vascular access. 
Central venous catheters were covered in 58% of coun-
tries, and arteriovenous fistula or graft creation was 
covered in 54% of countries (online supplemental tables 
3 and 4). Access creation for PD was publicly funded in 
54% of countries (online supplemental table 5). Trans-
plantation surgery was covered by full or partial public 
funding in 53% of countries. Coverage increased with 
World Bank income level (low, 50%; lower middle, 74%; 
upper middle, 85%; and high, 98%). Countries in Eastern 
and Central Europe, the Middle East, the NIS and Russia, 
North and East Asia and Western Europe had the highest 
coverage for all surgical aspects of kidney care, including 
both dialysis access creation and kidney transplantation. 
Coverage for all aspects of KRT was provided by 75% 
of high- income, 43% of upper- middle- income, 19% of 
lower- middle- income and 0% of low- income countries 
(online supplemental figure 2).
Funding for conservative kidney management
Overall, public funding for KRT was more common than 
funding for conservative kidney management (online 
supplemental figure 2). Globally, 28% of countries 
provided full public funding for conservative kidney 
management, with an additional 20% charging some 
fees at point of delivery (online supplemental table 6). 
Conservative kidney management was more commonly 
excluded from public funding in South Asia, the NIS and 
Russia, Africa, Oceania and South East Asia (OSEA) and 
Latin America. Management of ESKD complications (ie, 
Figure 2 Haemodialysis (HD) to peritoneal dialysis (PD) cost ratio.
Figure 3 Funding models for kidney replacement therapy (KRT). NGOs, non- governmental organisations; KRT, rapid 
transformational therapy.
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anaemia, bone disease, and malnutrition) was more likely 
to be excluded from coverage in South Asia, the NIS and 
Russia, Africa and North America.
Universal health coverage
Among the countries that provided at least some public 
funding for KRT, 75% provided coverage to all citizens. 
However, the level of UHC for KRT varied significantly 
by region, with predictably higher rates with increasing 
country income level. UHC for KRT was provided in 
Eastern and Central Europe, the NIS and Russia and 
Western Europe, with the lowest rates of UHC provided 
in the Middle East (27%), followed by South Asia (50%), 
North America (56%), and Africa (56%) (figure 4).
Out-of-pocket costs for KRT
Globally, 8% of patients were required to pay the entirety 
of HD costs, while 27% of patients did not pay any out- 
of- pocket costs. Similarly, for PD, patients in 5% of coun-
tries paid 100% of costs (Albania, Botswana, Bangladesh, 
Democratic Republic of Congo, Croatia, Kosovo, Moldova 
and New Caledonia), while 23% of patients paid no fees. 
For transplantation, patients in 9% of countries paid 
100% of costs (Albania, Croatia, Ghana, Haiti, Jordan, 
Moldova, Nigeria, Saudi Arabia, Syrian Arab Republic 
and the United Arab Emirates), while patients in 31% of 
countries paid nothing (online supplemental figure 2).
In general, residents of lower- income- countries had a 
higher likelihood of bearing the full burden of HD costs. 
Patients paid 100% of HD costs in 14% of low- income 
countries, compared with 11% of lower- middle- income, 
7% of upper- middle- income and 4% of high- income 
countries. Conversely, patients paid no out- of- pocket 
costs for HD in 39% of high- income countries, compared 
with 20% of upper- middle- income, 17% of lower- middle- 
income and 23% of low- income countries. Globally, a 
small proportion of patients paid 100% of costs for PD, 
regardless of the country’s income level (low, 5%; lower 
middle, 9%; upper middle, 5%; and high, 4%). Full 
funding for PD followed a pattern similar to that for 
HD, with patients in 0% of low- income, 14% of lower- 
middle- income, 24% of upper- middle- income and 36% 
of high- income countries paying no fees. Very few low- 
income countries reported on the affordability of kidney 
transplantation, with information available for only five 
countries (Cambodia, Burundi, Democratic Republic of 
Congo, Nepal and Tanzania). Patients bore the full costs 
of transplantation in 20% of low- income, 17% of lower- 
middle- income, 6% of upper- middle- income and 6% of 
high- income countries. Full coverage for transplantation 
was available for patients in 20% of low- income, 17% of 
lower- middle- income, 24% of upper- middle- income and 
44% of high- income countries (figure 5).
Within-country variability in ESKD care delivery
Intracountry variation in the delivery of ESKD care was 
reported in 40% of countries, with the highest varia-
tion in OSEA, Africa, South Asia and North America. 
Intracountry variation was highest in low- income (65%) 
and upper- middle- income (64%) countries, slightly lower 
in lower- middle- income countries (46%) and much lower 
in high- income countries (18%). In addition, variability 
between children and adults in care delivery and access to 
KRT increased as country income level decreased.
Oversight of ESKD care
All high- income countries reported the existence of 
ESKD management and oversight systems; however, 13% 
of low- income, 3% of lower- middle- income and 10% of 
upper- middle- income countries lacked such systems. 
The majority of oversight took place at the national level 
(56%); the hospital, trust or organisational level (38%); 
Figure 4 Extent of universal coverage for kidney replacement therapy (KRT). UHC, universal health coverage.
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or the provincial, regional or state level (21%) (online 
supplemental table 7).
DISCUSSION
Full public funding for both conservative kidney manage-
ment and KRT decreased as World Bank income level 
decreased. Lower country income level was also asso-
ciated with poorer health system oversight and higher 
levels of intracountry variability in care delivery.
UHC is defined by the WHO as ‘access to necessary 
promotive, preventive, curative and rehabilitative health 
interventions for all at an affordable cost’. The aim of 
UHC is to avoid catastrophic out- of- pocket expenses for 
access to health services, defined as healthcare expendi-
tures exceeding 10% of household income.14 Financial 
protection is lacking globally and disproportionately 
affects those who are most vulnerable: the poor, minority 
populations, rural populations and women and chil-
dren.14 Unfortunately, this study revealed that countries 
in the Middle East, South Asia, North America and Africa 
did not provide UHC for KRT. Globally, a significant 
proportion of people living with ESKD paid for treatment 
entirely out of pocket.
In lower- middle- income countries where 100% of costs 
are out of pocket, a single month of essential medicines 
for kidney care can cost up to 18 days’ wages.1 Such out- 
of- pocket costs relative to wages are even more stark for 
expensive kidney care treatments, such as immunosup-
pressive medications and dialysis consumables. A study 
of Organisation for Economic Co- operation and Devel-
opment countries demonstrated an association between 
higher drug costs and out- of- pocket expenses, with 
poorer medication compliance among dialysis patients.15 
In India, a study demonstrated higher adherence to 
dialysis three times per week when external financial 
support was provided and high rates of dialysis cessa-
tion (60%) in the absence of support.15 In sub- Saharan 
Africa, over 95% of patients with ESKD were unable to 
access dialysis due to financial and other barriers. Among 
those with access, only 10% of adults remained on dial-
ysis beyond 3 months, resulting in high mortality.16 The 
majority of attrition occurred within 2 weeks of dialysis 
commencement due to an inability to pay the mean cost 
of US$100–150 per session.16 Lack of UHC for ESKD 
treatment inevitably leads to out- of- pocket costs and 
adverse outcomes. Coverage for transplantation without 
coverage for immunosuppressant medications, antihyper-
tensives or vaccinations, for example, resulted in subop-
timal outcomes and reduced the cost- effectiveness of the 
upfront investment in the transplantation process.17 Ulti-
mately, the decision to provide funding for healthcare is 
a reflection of a country’s priorities. Despite a per capita 
income of only US$400, citizens in Rwanda enjoy access 
to basic health services, with the country allocating 19.5% 
of its total annual spending to healthcare. There are 182 
other WHO member states with comparable or higher 
GDPs that are much farther away from achieving UHC.18
Conservative kidney management is important, given 
resource constraints (both patient and system related) in 
many countries that limit access to KRT.9 In this study, 
only a minority of countries provided full public funding 
for conservative kidney management, with some regions 
excluding it from public funding altogether. Choice- 
restricted conservative kidney management can be 
provided in settings where KRT is not an option due to 
insufficient resources.17 Despite a lack of choice, conser-
vative kidney management is certainly preferable to 
a complete lack of care. Interventions should focus on 
delaying disease progression, minimising adverse effects 
and complications, managing active symptoms, providing 
Figure 5 Proportion of treatment costs paid directly by patients, International Society of Nephrology region and World Bank 
income group. HD, haemodialysis; OSEA, Oceania and South East Asia; PD, peritoneal dialysis.
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psychosocial support for patients and their families and 
promoting shared decision making in all domains of 
care.17
In the majority of developing countries, only 5% of 
those with ESKD as a complication of diabetes or hyper-
tension can access KRT, leaving millions without care.19 
Widespread access to KRT is unlikely to be established 
quickly, particularly in low- income and lower- middle- 
income countries, and the minimisation of suffering 
and maximisation of quality of life should be priori-
tised. Alongside conservative kidney management, the 
role of preventative health should not be overlooked 
as a cost- effective intervention. Rates for hypertension 
and diabetes are projected to increase by 80%–100% in 
developing countries in the coming two decades and by 
20%–50% in developed countries. At present, 25%–45% 
of patients receiving KRT in developing countries have 
ESKD secondary to one of these conditions.19 Thus, there 
is significant potential for early intervention to prevent 
the onset and progression of CKD.
Economic factors were identified as top barriers to 
optimal ESKD care globally. Perhaps unsurprisingly, 
only 28% of countries provided full public funding for 
conservative kidney management, and 43% provided 
full coverage of all KRT modalities. An adequate health 
financing system is defined by the WHO as one that 
raises adequate funds for health, ensures people can use 
needed services while being protected from financial 
catastrophe or impoverishment and provides incentives 
for healthcare providers and users to be efficient.8
Four strategies identified to increase healthcare 
funding are improving the efficiency of taxation, repri-
oritising government budgets towards health, evaluating 
innovative financing mechanisms and increasing develop-
ment assistance for health.6 However, it is also important 
to acknowledge that scaling up of services does not always 
require increased investment; often, more can be done 
with existing resources by appropriately matching care 
provision with the burden of disease, properly distrib-
uting healthcare providers, improving the organisation 
of primary care, reducing disparities in health access and 
ensuring interventions are evidence based and cost effec-
tive.9 Major sources of healthcare inefficiency identified 
by the WHO include an inefficient or inappropriate mix 
of funding between prevention and treatment, a lack of 
guidelines to maintain clinical care standards and weak 
procurement strategies that lead to the underuse of 
generic medications and overuse of substandard or coun-
terfeit medicines.18
Ultimately, no country is able to provide coverage for 
all available life- prolonging therapies for all citizens. 
Making decisions about which therapies to cover is crit-
ically important to maximise impact, with ongoing eval-
uation to keep pace with changes in resource availability. 
A framework exists for low- income and middle- income 
country governments to use when considering establish-
ment or scaling up of programmes for prevention and 
management of kidney failure. This framework prioritises 
preventative care due to high cost efficiency and poten-
tial for integration into other non- communicable disease 
prevention programme.20 Alongside prevention, conser-
vative care programmes are recommended. Within KRT, 
kidney transplantation is the most cost effective; however, 
this may be limited by lack of surgical expertise or lack of 
appropriate safeguards to facilitate organ donation and 
prevent organ trafficking. In most contexts, PD is equally 
effective but more cost effective in the majority of low- 
resource settings compared with HD, but local variation 
may exist depending on cost and local supply of PD fluid.20 
When UHC was first introduced in Thailand in 2002, a 
limit of 100 000 baht per quality- adjusted life year was set 
by the National Health Security Office. This meant that 
although prescription medicines, ambulatory care, hospi-
talisation, disease prevention and health promotion were 
offered free of charge, KRT, which costed 400 000 baht 
per patient per year, was not. When resources increased 
after the country recovered from the Asian economic 
crisis, the scheme was subsequently expanded in 2008 to 
include KRT.18 21 Health systems in all countries will face 
increasing financial strain in providing adequate care for 
an increasing global burden of CKD. It is therefore crit-
ically important that countries make ongoing financial 
commitments to provide equitable health coverage and 
UHC and use available resources efficiently.
In addition to appropriate health financing, appro-
priate health governance involving both oversight and 
priority setting, as well as subsequent evaluation of prog-
ress and outcomes, is crucial for optimal ESKD care. 
Developing effective policy requires defining problems, 
considering policy alternatives and evaluating costs versus 
benefits to create action plans that accurately inform 
health financing decisions and subsequent quantitative 
and qualitative evaluations of outcomes.9 With the excep-
tion of high- income countries, a significant proportion of 
countries currently lack ESKD management systems and 
oversight.
Informed priority setting requires identifying locally 
relevant risk factors and developing policies and plans 
that address the unique needs of the population.1 For 
example, Mesoamerican, Balkan and Chinese herbal 
nephropathies are associated with region- specific risk 
factors.9 Effective policy also plays a pivotal role in disease 
prevention. Aggressive tobacco taxation has led to a 
reduction in smoking prevalence and has been shown in 
some countries to reduce ethnic inequalities in smoking 
behaviours; typically, higher smoking rates are observed 
in minority groups.22 Similarly, taxation of sugary bever-
ages in Mexico has reduced accessibility to and the appeal 
of unhealthy foods and provides an additional revenue 
stream for health expenditures.1 Just over 1 year after 
the introduction of the tax, sugar- sweetened beverage 
consumption in Mexico declined by 12%, with the 
greatest reduction among households with low socioeco-
nomic status, which are associated with disproportionate 
rates of obesity.23 Reduction in unhealthy food consump-
tion at the population level reduces the incidence of 
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hypertension, diabetes and obesity; all of which are 
important and modifiable risk factors for CKD.
Health systems must also place a specific emphasis on 
the establishment of equitable health access. Despite 
establishing UHC in 2002, residents of Thailand experi-
enced inequitable access to KRT across three healthcare 
schemes, with some having no access at all. To combat 
inequality, Thailand introduced a ‘PD first’ policy in 2008, 
which required more dialysis centres to be established and 
more trained staff to be hired, thereby increasing access 
to KRT, which has improved both survival and quality of 
life for residents with ESKD.24
Reasonable health expenditure is necessary but insuf-
ficient to achieve good health outcomes. The USA, for 
example, spends 17.8% of its gross domestic product 
(GDP) on healthcare—more than the average among 
all high- income countries (11.5%) and more per capita 
than any other nation.21 Despite this, Americans have 
the lowest life expectancy, highest infant mortality and 
highest percentage of overweight or obese adults among 
these countries.25 This healthcare paradox is often 
attributed to prioritising curative treatment over preven-
tative health, social determinants of health and equitable 
access.26 Ineffective oversight leads to suboptimal policy 
informing the allocation of funds for healthcare, which in 
turn leads to resource strain and poor health outcomes. 
This again highlights the importance of prioritising the 
development of oversight mechanisms in upper- middle- 
income, lower- middle- income and low- income countries.
Global optimisation of ESKD care requires careful 
management of limited resources and the establish-
ment and strengthening of health oversight and gover-
nance mechanisms to manage competing priorities. The 
high cost of KRT limits the feasibility of public funding 
in many countries, particularly in low- resource settings. 
This makes a focus on ESKD prevention particularly 
important, along with increasing availability of conserva-
tive kidney management. HD tended to be less expensive 
than PD in lower- middle- income countries. Countries that 
are looking to establish KRT programmes should care-
fully evaluate costs versus benefits in a context- specific 
manner to determine the suitability of HD compared 
with PD (including consideration of home- based treat-
ment options) and implement appropriate compensa-
tory schemes to encourage its use and provide equitable 
access. Importantly, this study found that cost estimates 
were only available for HD in low- income countries, 
which made it impossible to make such comparisons.
Looking ahead, the increasing prevalence of CKD risk 
factors (diabetes, hypertension and obesity), rising global 
temperatures due to climate change, changes in disease 
epidemiology (ie, increased risk of CKD of unknown 
aetiology and Central American nephropathy) and a 
demographical shift towards an ageing population are 
likely to increase the burden of CKD. Emerging technol-
ogies may provide additional tools to tackle CKD. Mobile 
phones have already significantly enhanced the capacity 
to spread health information and improve health literacy, 
as well as reduce barriers, including long travel times to 
seek medical assistance.27 Telemedicine is already being 
used to increase capacity for and access to kidney care for 
populations in low- resource settings and for underserved 
populations in high- income settings.27 In the first major 
dialysis technology breakthrough since its invention in 
1943, the world’s first affordable dialysis machine was 
unveiled in 2016 as a competition entry for the Affordable 
Dialysis Prize. The prize was a global challenge to create 
a low- cost device (costing less than US$1000 to manufac-
ture and able to run on less than US$5 per day) that is 
powered by solar energy and can purify any water source. 
Pilot testing for the device is scheduled to begin in 2020.28 
If successful, the device has the potential to revolutionise 
the global delivery of dialysis.
Strengths
This study included 160 countries (covering 98% of the 
world’s’ population), thereby providing a comprehensive 
overview of the state of kidney care around the world. 
The use of a combination of data from desk research 
and survey responses from on- the- ground stakeholders 
provided a holistic perspective of kidney care in partici-
pating countries. The 2019 report was the second itera-
tion of the GKHA and allowed for monitoring of progress 
made since the previous report and identification of new 
and ongoing gaps.
Limitations
These cross- sectional studies captured a snapshot of 
kidney care at a particular point in time and may not have 
been representative of the time period of interest. While 
the cross- sectional design was well suited to facilitate 
comparisons of global kidney care between countries and 
regions, they were offset by a relative lack of granular detail 
required to guide specific programme and systematic 
change. Data available from low- income countries were 
limited compared with middle- income and high- income 
countries, which led to challenges in identifying specific 
gaps in care provision in nations where this was greatly 
needed. This is a well- documented issue in low- resource 
settings and continues to limit the conclusions that can be 
drawn regarding the state of health and health systems in 
these countries. Not all countries had a consumer organ-
isation to represent the patient perspective.
CONCLUSION
From 2017 to 2019, there have been marginal improve-
ments in health systems oversight; overall, fewer coun-
tries have no structured governance. However, economic 
factors remain a top barrier to ESKD care, with subop-
timal rates of UHC, inadequate public funding for both 
KRT and conservative kidney management and ongoing 
inequalities in care delivery within countries. The poten-
tial for emerging technologies to improve affordability 
and access to CKD care and to enhance the capacity of 
health systems, particularly in low- resource settings, is 









pen: first published as 10.1136/bm




9Yeung E, et al. BMJ Open 2021;11:e047245. doi:10.1136/bmjopen-2020-047245
Open access
promising. However, countries must commit to providing 
UHC, ensure adequate focus on preventative health, 
establish conservative kidney management pathways for 
those without KRT access, improve health financing by 
increasing healthcare funding and reducing spending 
inefficiencies and establish strong governance systems 
that engage in evidence- based priority setting and moni-
toring to be well positioned for the adoption and imple-
mentation of these technologies. This second iteration of 
the GKHA can be used as a marker of progress in global 
capacity for the provision of CKD care moving forward.
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